The PLAJEX 2.25 mL with Tapered Needle is specifically designed to meet the demands of the Biotech market
Terumo Pharmaceutical Solutions (TPS), a division of Terumo Corporation and a leading manufacturer of primary container, injection and infusion therapy devices, has launched a ready-to-fill polymer syringe for challenging biotech drugs with larger volume.
TPS is a manufacturer of primary container, injection and infusion therapy devices.
The PLAJEX 2.25 mL with Tapered Needle is specifically designed to meet the demands of the Biotech market, making it suitable for complex drug applications, such as high viscosity biotech medications.
The syringe enables pharmaceutical customers to offer a safe, easy-to-use, and effective treatment option that maximises patient convenience.
Yuki Takeuchi, Global Product Manager for PLAJEX platform, said that the syringes are designed to address the unmet needs of biotech companies that are dealing with challenging and highly viscous biologic drugs, such as highly concentrated monoclonal antibodies.
Takeuchi continued: “With the rise of biologic formulations, and the increasing trend in self-administration, a drug delivery device needs to be easy-to-use, be able to deliver drugs safely, comfortably with suitable force. Our latest offering with Tapered Needle technology addresses the challenge of delivering highly viscous drugs without compromising patient comfort.”
As the latest addition to the PLAJEX range, these primary container solutions come sterilised, and ready for filling, offering silicone oil-free, tungsten-free and glue-free containers made with precise polymer molding technology to provide tight dimensional tolerances.
Terumo’s proprietary i-coating stopper technology eliminates the need of silicone oil in the syringe system while providing consistent and predictable break-loose and glide forces.
The PLAJEX 2.25 mL with Tapered Needle is compatible with some of marketed injection devices, while additional compatibility studies are ongoing with leading device providers.
TPS will help customer’s smooth fill and finish integration either by offering Terumo’s in-house CDMO (Contract Development and Manufacturing Organisation) capability, or supporting drug filling sites selected by customers.
Anil Busimi, VP Strategy & Marketing, added: “Terumo is in a unique position being able to offer an integrated solution of primary container and fill & finish capability. We continue to expand our portfolio with innovative injectable drug delivery solutions to meet pharma customers and patients’ needs.”